Skip To Main Content
Ruchi Pandey on Muck Rack

Ruchi Pandey

As seen in: Color Research & Application, Archives of Public Health, The Astronomical Journal, Cell Press, EIN News, Amar Ujala, The Journal of Clinical Investigation, EIN Presswire, The Journal of Allergy & Clinical Immunology

Get in touch with Ruchi

Contact Ruchi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Springbase Launches Multilingual Voice-to-Agent Capabilities, Turning Spoken Ideas into Finished Work

|
By Ruchi Pandey
| EIN Presswire
Disruptive capability helps users globally turn spoken ideas into research, plans, workflows, code, websites and digital products A first-of-a-kind experience that moves beyond dialogue into execution, with explainability behind every decision, ushering a new era where anyone can create sophisticated digital experiences.” — Bharat Golchha NEWARK, DE, UNITED STATES, July 7, 2026 / EINPresswire.com/ -- InnoventuresAI Inc., headquartered in Delaware, United States of America, today announced the...
Open in Who Shared View Duplicates (58) Issue with article?

Innoventures AI Inc. Launches Springbase.AI

|
By Ruchi Pandey
| EIN Presswire
First-of-Its-Kind AI OS for Output Acceleration Integrates Chat and Professional Context to Generate Ready to Use Business Workflows and Content For individuals, teams, and organisations serious about productivity, Springbase.ai provides a new way to work with AI.” — Bharat Golchha NEWARK, DE, UNITED STATES, June 15, 2026 / EINPresswire.com/ -- InnoventuresAI Inc., headquartered in Delaware, United States of America, has announced the official launch of Springbase.ai, an end-to-end AI...
Open in Who Shared View Duplicates (94) Issue with article?

Alkynyl nicotinamides show antileukemic activity in drug-resistant acute myeloid leukemia

|
By Baskar Ramdas, Neetu Dayal, Ruchi Pandey, Elizabeth Larocque
| The Journal of Clinical Investigation
Abstract Activating mutations of FLT3 contribute to deregulated hematopoietic stem and progenitor cell (HSC/Ps) growth and survival in patients with acute myeloid leukemia (AML), leading to poor overall survival. AML patients treated with investigational drugs targeting mutant FLT3, including Quizartinib and Crenolanib, develop resistance to these drugs.
Open in Who Shared Issue with article?
See all 15 articles